Long-term impact of invasive meningococcal disease in children: SEINE study protocol

PLoS One. 2022 May 26;17(5):e0268536. doi: 10.1371/journal.pone.0268536. eCollection 2022.

Abstract

Introduction: Invasive meningococcal disease (IMD) is still an important cause of mortality in children and survivors can have significant long-term disabling sequelae. There are few prospective studies looking at the long term neuropsychological and developmental consequences of IMD in surviving children, and the rate of sequelae may be underestimated. The SEINE study aims to have a more reliable estimate of the real rate of sequelae by assessing the long-term physical, neuropsychological, learning disorders and sensory sequelae of IMD in children and adolescents and by assessing the post-traumatic stress in parents.

Methods and analysis: The SEINE study is a multicentre, prospective, non-randomized, interventional study based on the French bacterial meningitis surveillance network. The study will include 100 children aged from birth to 15 years old, hospitalized in a Paris area paediatric ward for a meningococcal meningitis or a purpura fulminans between 2010 and 2019. The first outcome will assess long-term sequelae (physical, neurological, or sensory) measured by a general clinical and neurological examination, a neurocognitive assessment, learning development, a pure tone audiometry and an ophthalmic examination. The second outcome will assess the long-term post-traumatic stress in parents measured by the Impact of Event Scare Revised questionnaire.

Perspectives: By providing a better estimation of the rate of sequelae in children and offering an adapted follow-up of these children, we believe that the SEINE study will help to improve the management of patients surviving IMD.

Trial registration number: NCT04685850.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Disease Progression
  • Humans
  • Meningitis, Meningococcal* / complications
  • Meningococcal Infections* / complications
  • Meningococcal Infections* / epidemiology
  • Prospective Studies
  • Surveys and Questionnaires
  • Survivors

Associated data

  • ClinicalTrials.gov/NCT04685850

Grants and funding

Our study was funded by Sanofi Pasteur, under a collaborative agreement with ACTIV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.